Mirdametinib (MEK Inhibitor) ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
34神経線維腫症1

34. 神経線維腫症


臨床試験数 : 137 薬物数 : 213 - (DrugBank : 76) / 標的遺伝子数 : 87 - 標的パスウェイ数 : 200
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05028166
(ClinicalTrials.gov)
October 1, 202124/8/2021Individual Patient Compassionate Use of MirdametinibNeurofibromatosis Type 1-Associated Plexiform Neurofibromas;Histiocytic Neoplasm;Other MAP-K Pathway Driven DiseasesDrug: Mirdametinib (MEK Inhibitor)SpringWorks Therapeutics, Inc.NULLAvailable2 YearsN/AAllNULL